LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF
    1.
    发明申请
    LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF 审中-公开
    5-HT6受体的配体,药物组合物,其生产和使用方法

    公开(公告)号:US20110046368A1

    公开(公告)日:2011-02-24

    申请号:US12741006

    申请日:2007-11-15

    摘要: The invention relates to novel ligands of 5-HT6 receptor, to a pharmaceutical composition containing said novel ligands of 5-HT6 receptor as active component and to novel medicaments used for humans and warm-blooded animals for treating diseases and conditions of central nervous system, in pathogenesis of which neuromediator systems induced by 5-HT6 receptors are playing an essential role.Azaheterocyclic compounds of the general formula 1 or racemates, or optical or geometrical isomers, or pharmaceutically acceptable salts and/or hydrates thereof are used as 5-HT6 ligands. Wherein R2 and R3 independently of each other represent an amino group substituent selected from hydrogen; substituted carbonyl; substituted aminocarbonyl; substituted aminothiocarbonyl; substituted sulphonyl; C1-C5-alkyl optionally substituted by: C6-C10-arylaminocarbonyl, heterocyclyl, C6-C10-arylaminocarbonyl, C6-C10-arylaminothiocarbonyl, C5-C10-azaheteroaryl, optionally substituted carboxyl, nitryl group, optionally substituted aryl; R1k represents from 1 to 3 substituents of cyclic system, independent of each other and selected from hydrogen, optionally substituted C1-C5-alkyl, C1-C5-alkoxy, C1-C5-alkenyl, C1-C5-alkynyl, halogen, trifluoromethyl, CN-group, carboxyl, optionally substituted aryl, optionally substituted heterocyclyl, substituted sulfonyl, optionally substituted carboxyl; the solid line accompanied by the dotted line represents a single or a double bond; n=1, 2 or 3.

    摘要翻译: 本发明涉及含有5-HT 6受体作为活性成分的所述新型配体的药物组合物和用于人和用于治疗中枢神经系统疾病和病症的温血动物的新型药物的5-HT 6受体的新配体, 在5-HT6受体诱导的神经调节因子的发病机理中起着重要的作用。 通式1的氮杂环化合物或其外消旋体或光学或几何异构体或其药学上可接受的盐和/或水合物用作5-HT 6配体。 其中R2和R3彼此独立地表示选自氢的氨基取代基; 取代羰基; 取代的氨基羰基; 取代的氨基硫代羰基; 取代磺酰基; 任选被C 6 -C 10芳基氨基羰基,杂环基,C 6 -C 10 - 芳基氨基羰基,C 6 -C 10 - 芳基氨基硫代羰基,C 5 -C 10 - 氮杂杂芳基,任选取代的羧基,硝基,任选取代的芳基取代的C 1 -C 5 - 任选取代的C 1 -C 5 - 烷基,C 1 -C 5 - 烷氧基,C 1 -C 5 - 烯基,C 1 -C 5 - 炔基,卤素,三氟甲基, CN-基团,羧基,任选取代的芳基,任选取代的杂环基,取代的磺酰基,任选取代的羧基; 伴随虚线的实线表示单键或双键; n = 1,2或3。

    LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE
    2.
    发明申请
    LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE 审中-公开
    ALPHA-ADRENOCEPTORS,DOPAMINE,HISTAMINE,IMIDAZOLINE和SEROTONIN受体的配体及其用途

    公开(公告)号:US20110039825A1

    公开(公告)日:2011-02-17

    申请号:US12810013

    申请日:2008-12-19

    摘要: The invention relates to novel ligands the broad spectrum of biological activity of which includes simultaneously α-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors and serotonin receptors, among them serotonin 5-HT7 receptors, which are compounds of general formula 1 in the form of free bases, geometrical isomers, racemic mixtures or individual optical isomers, pharmaceutically acceptable salts and/or hydrates, wherein: R1 is a substituent of amino group, selected from hydrogen, optionally substituted C1-C4 alkyl, acyl, heterocyclyl, alkoxycarbonyl, substituted sulfonyl; R2 is a substituent of cyclic system, selected from hydrogen, halogen, optionally substituted C1-C4 alkyl, CF3, CN, alkoxy, alkoxycarbonyl, carboxyl, heterocyclyl or substituted sulfonyl; Ar is optionally substituted aryl not necessarily annalated with heterocyclyl, or optionally substituted aromatic heterocyclyl; W is optionally substituted (CH2)m group, optionally substituted CH═CH group, optionally substituted CH2—CH═CH group, C≡C group, SO2 group; n=1, 2; m=1, 2, 3; solid line accompanied by dotted line, i.e. may represent single or double bond. The invention also relates to active ingredients, pharmaceutical compositions comprising the said ligands as active ingredients; to novel medicaments useful for treatment of diseases and conditions of central nervous system (CNS) of humans and warm-blooded animals.

    摘要翻译: 本发明涉及其具有广谱生物活性的新配体,其包括同时α-肾上腺素受体,多巴胺受体,组胺受体,咪唑啉受体和5-羟色胺受体,其中5-羟色胺5-HT 7受体是通式1的化合物,其形式为 游离碱,几何异构体,外消旋混合物或单独的光学异构体,药学上可接受的盐和/或水合物,其中:R1是氨基的取代基,其选自氢,任选取代的C 1 -C 4烷基,酰基,杂环基,烷氧基羰基,取代的 磺酰基 R2是选自氢,卤素,任选取代的C 1 -C 4烷基,CF 3,CN,烷氧基,烷氧基羰基,羧基,杂环基或取代的磺酰基的环状体系的取代基。 Ar是任选取代的芳基,不一定与杂环基或任选取代的芳族杂环基取代; W是任选取代的(CH 2)m基团,任选取代的CH = CH基团,任选取代的CH 2 -CH = CH基团,C≡C基团,SO 2基团; n = 1,2; m = 1,2,3。 伴有虚线的实线即可表示单键或双键。 本发明还涉及活性成分,包含所述配体作为活性成分的药物组合物; 用于治疗人类和温血动物的中枢神经系统(CNS)的疾病和病症的新型药物。

    2-amino-3-sulphonyl-tetrahydro-pyrazolo[1,5-A]pyrido-pyrimidine antagonists of serotonin 5-HT6 receptors, methods for the production and use thereof
    7.
    发明授权
    2-amino-3-sulphonyl-tetrahydro-pyrazolo[1,5-A]pyrido-pyrimidine antagonists of serotonin 5-HT6 receptors, methods for the production and use thereof 有权
    5-羟色胺5-HT6受体的2-氨基-3-磺酰基 - 四氢 - 吡唑并[1,5-A]吡啶并 - 嘧啶拮抗剂,其制备方法和用途

    公开(公告)号:US08552017B2

    公开(公告)日:2013-10-08

    申请号:US12937718

    申请日:2009-04-30

    CPC分类号: C07D471/14 A61K31/519

    摘要: The invention relates to serotonin 5-HT6 receptor antagonists—novel 2-amino-3-arylsulfonyl-6,7,8,9-tetrahydropyrazolo[1,5-a]pyrido[4,3-e]pyrimidines and substituted 2-amino-3-arylsulfonyl-5,6,7,8-tetrahydropyrazolo[1,5-a]pyrido[4,3-d]pyrimidines, drug substances and pharmaceutical compositions comprising the said drug substances as the said compounds, and also to method of prophylaxis and treatment of various diseases of central nervious system in humans and animals pathogenesis of which is associated with serotonin 5-HT6 receptors including cognitive and neurodegenerative diseases.Substituted 2-amino-3-arylsulfonyl-6,7,8,9-tetrahydropyrazolo[1,5-a]pyrido[4,3-e]pyrimidines of the general formula 1 and substituted 2-amino-3-arylsulfonyl-5,6,7,8-tetrahydropyrazolo[1,5-a]pyrido[4,3-d]pyrimidines of the general formula 2 and pharmaceutically acceptable salts and/or hydrates thereof. wherein: Ar is optionally substituted aryl or optionally substituted heteroaryl; R1 is hydrogen, optionally substituted C1-C3 alkyl, C1-C4 alkyloxycarbonyl; R2 is hydrogen, halogen or optionally substituted C1-C3 alkyl; R13 and R23 represent optionally alike: hydrogen, optionally substituted C1-C3 alkyl or R13 and R23 together with the nitrogen atom to which they are attached form an optionally substituted azaheterocycle.

    摘要翻译: 本发明涉及5-羟色胺5-HT 6受体拮抗剂 - 新型2-氨基-3-芳基磺酰基-6,7,8,9-四氢吡唑并[1,5-a]吡啶并[4,3-e]嘧啶和取代的2-氨基 -3-芳基磺酰基-5,6,7,8-四氢吡唑并[1,5-a]吡啶并[4,3-d]嘧啶,药物物质和药物组合物,其包含作为所述化合物的所述药物物质, 预防和治疗人类和动物的中枢神经系统的各种疾病,其发病机制与血清素5-HT6受体(包括认知和神经变性疾病)相关。 通式1的取代的2-氨基-3-芳基磺酰基-6,7,8,9-四氢吡唑并[1,5-a]吡啶并[4,3-e]嘧啶和取代的2-氨基-3-芳基磺酰基-5 ,6,7,8-四氢吡唑并[1,5-a]吡啶并[4,3-d]嘧啶,及其药学上可接受的盐和/或水合物。 其中:Ar是任选取代的芳基或任选取代的杂芳基; R 1是氢,任选取代的C 1 -C 3烷基,C 1 -C 4烷氧基羰基; R2是氢,卤素或任选取代的C 1 -C 3烷基; R 13和R 23任选地相似:氢,任选取代的C 1 -C 3烷基或R 13和R 23与它们所连接的氮原子一起形成任选取代的杂环。

    (EN) 3-sulfonyl-pyrazolo[1,5-a] pyrimidines / antagonists of serotonin 5-HT6 receptors, methods for the production and the use thereof
    8.
    发明授权
    (EN) 3-sulfonyl-pyrazolo[1,5-a] pyrimidines / antagonists of serotonin 5-HT6 receptors, methods for the production and the use thereof 有权
    (EN)3-磺酰基 - 吡唑并[1,5-a]嘧啶/ 5-羟色胺5-HT 6受体的拮抗剂,生产方法及其用途

    公开(公告)号:US08552005B2

    公开(公告)日:2013-10-08

    申请号:US12812728

    申请日:2009-01-23

    CPC分类号: C07D487/04

    摘要: The present invention relates to novel substituted 3-(arylsulfonyl)pyrazolo[1,5-a]pyrimidines of general formula 1 pharmaceutically acceptable salts and/or hydrates, to novel serotonin 5-HT6 receptor antagonists, to novel drug substances, pharmaceutical compositions, medicaments and methods for their preparation and use for treatment and prophylaxis of pathological states and diseases of CNS, pathogenesis of which is associated with disturbance of serotonin 5-HT6 receptor activation.In compounds of general formula 1 Ar represents optionally substituted aryl or heterocyclyl; R1, R2 and R3 independently of each other represent hydrogen, C1-C3 alkyl or phenyl; R4 represents hydrogen, optionally substituted C1-C5 alkyl, substituted hydroxyl group or substituted sulfanyl group.

    摘要翻译: 本发明涉及通式1的药学上可接受的盐和/或水合物的新的取代的3-(芳基磺酰基)吡唑并[1,5-a]嘧啶新颖的5-羟色胺5-HT 6受体拮抗剂,新药物,药物组合物, 药物及其制备方法,用于治疗和预防CNS的病理状态和疾病,其发病机制与血清素5-HT6受体激活的干扰有关。 在通式1的化合物中Ar表示任选取代的芳基或杂环基; R 1,R 2和R 3彼此独立地表示氢,C 1 -C 3烷基或苯基; R 4表示氢,任选取代的C 1 -C 5烷基,取代的羟基或取代的硫烷基。

    Tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidines as antagonists of serotonin 5-HT6 receptors, methods for the production and use thereof
    10.
    发明授权
    Tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidines as antagonists of serotonin 5-HT6 receptors, methods for the production and use thereof 有权
    四氢吡唑并[1,5-a]吡啶并嘧啶作为5-羟色胺5-HT 6受体的拮抗剂,其生产和使用方法

    公开(公告)号:US08569318B2

    公开(公告)日:2013-10-29

    申请号:US12937720

    申请日:2009-04-30

    CPC分类号: C07D471/14 A61K31/519

    摘要: The present invention relates to serotonin 5-HT6 receptor antagonists-novel substituted 3-sulfonyl-6,7,8,9-tetrahydropyrazolo[1,5-a]pyrido[4,3-e]pyrimidines and substituted 3-sulfonyl-5,6,7,8-tetrahydropyrazolo[1,5-a]pyrido[4,3-d]pyrimidines, drug substances and pharmaceutical compositions comprising drug substances as the mentioned above compounds and to the method of prophylaxis and treatment of various conditions and diseases of central nervous system in humans and warm-blooded animals pathogenesis of which is associated with serotonin 5-HT6 receptors.In formulas 1 and 2 Ar is optionally substituted aryl or optionally substituted heterocyclyl; R1 is hydrogen, optionally substituted lower C1-C3 alkyl, substituted hydroxyl group, substituted sulfanyl group; R2 is hydrogen or optionally substituted C1-C3 alkyl; R3 is hydrogen, optionally substituted C1-C3 alkyl or tert.-butyloxycarbonyl.

    摘要翻译: 本发明涉及5-羟色胺5-HT 6受体拮抗剂 - 新型取代的3-磺酰基-6,7,8,9-四氢吡唑并[1,5-a]吡啶并[4,3-e]嘧啶和取代的3-磺酰基-5 ,6,7,8-四氢吡唑并[1,5-a]吡啶并[4,3-d]嘧啶,包含上述化合物的药物的药物和药物组合物,以及各种条件的预防和治疗方法 人类的中枢神经系统疾病和温血动物,其发病机制与血清素5-HT6受体有关。 在式1和2中Ar是任选取代的芳基或任选取代的杂环基; R1是氢,任选取代的低级C 1 -C 3烷基,取代的羟基,取代的硫烷基; R2是氢或任选取代的C 1 -C 3烷基; R3是氢,任选取代的C 1 -C 3烷基或叔丁氧基羰基。